Observation on the preliminary efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer

doi:10.3969/j.issn.1006-7795.2024.04.013

Abstract

Abstract: Objective To evaluate the efficacy of neoadjuvant programmed receptor 1 (PD-1) monoclonal antibody immunotherapy combined with chemotherapy for non-small cell lung cancer（NSCLC）. Methods This study included 176 patients with stage ⅠB~Ⅲ resectable NSCLC who received neoadjuvant immunotherapy combined with chemotherapy at our research center from January 2021 to December 2023. Totally, 159 patients (90.34%) received surgical treatment, including 42 cases of adenocarcinoma and 115 cases of squamous cell carcinoma. Results The median number of neoadjuvant treatment cycles was 2, with 4 patients (2.5%) achieving complete response (CR), 115 patients (72.3%) achieving partial response (PR), and 40 patients (25.2%) assessed as stable disease (SD) with only 2 cases of tumor enlargement; After surgery, 96 patients (60.4%, 95% CI: 52.7%-68.1%) achieved major pathological response (MPR), and 74 patients (46.5%, 95% CI: 38.7%-54.4%) achieved pathological complete response (pCR); Multivariate analysis showed that gender and programmed ligand 1 (PD-L1) significantly influenced the rates of MPR and pCR. Conclusion Neoadjuvant immunotherapy combined with chemotherapy showed initial efficacy in resectable stage ⅠB~Ⅲ NSCLC, and the expression level of PD-L1 may be a predictive factor for MPR and pCR.

Key words: neoadjuvant chemotherapy, PD-1 monoclonal antibody, , non-small cell lung cancer（NSCLC）, efficacy

CLC Number:

R734.2

Wu Zhaozhen, Zheng Hua, Sheng Shuyan, Zhang Quan, Zhang Hui, Li Jie, Lyu Jialin, Qian Zhe, Wang Shouzheng, Li Xi , Hu Ying. Observation on the preliminary efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer[J]. Journal of Capital Medical University, 2024, 45(4): 642-648.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.013

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/642

References

［1］ Siegel R L, Giaquinto A N, Jemal A. Cancer statistics, 2024［J］. CA Cancer J Clin, 2024, 74(1): 12-49.
［2］ Forde P M, Chaft J E, Smith K N, et al. Neoadjuvant PD-1 blockade in resectable lung cancer［J］. N Engl J Med, 2018, 378(21): 1976-1986.
［3］ Brown J S, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed［J］. Br J Cancer, 2018, 118(3): 312-324.
［4］ Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy［J］. Immunity, 2016, 44(2): 343-354.
［5］ Godoy L A, Chen J, Ma W J, et al. Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives［J］. Biomark Res, 2023, 11(1): 7.
［6］ Forde P M, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer［J］. N Engl J Med, 2022, 386(21): 1973-1985.
［7］ Forde P M, Spicer J, Girard N, et al. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816［J］. J Thorac Oncol, 2023, 18(4Suppl): S89-S100.
［8］ Provencio M, Nadal E, González-Larriba J L, et al. Perioperative nivolumab and chemotherapy in stage Ⅲ non-small-cell lung cancer［J］. N Engl J Med, 2023, 389(6): 504-513.
［9］ Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer［J］. N Engl J Med, 2023, 389(6): 491-503.
［10］ Heymach J V, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer［J］. N Engl J Med, 2023, 389(18): 1672-1684.
［11］ Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial［J］. JAMA, 2024, 331(3): 201-211.
［12］ Houda I, Dickhoff C, Uyl-de Groot C A, et al. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe［J］. Lancet Reg Health Eur, 2024, 38: 100840.
［13］ Chansky K, Detterbeck F C, Nicholson A G, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer［J］. J Thorac Oncol, 2017, 12(7): 1109-1121.
［14］ Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228-247.
［15］ Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies［J］. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.
［16］国家肿瘤质控中心肺癌质控专家委员会. 非小细胞肺癌新辅助治疗疗效病理评估专家共识［J］. 中华病理学杂志, 2021, 50(9): 1002-1007.
［17］ Matzner P, Sandbank E, Neeman E, et al. Harnessing cancer immunotherapy during the unexploited immediate perioperative period［J］. Nat Rev Clin Oncol, 2020, 17(5): 313-326.
［18］齐畅, 田攀文, 李为民. 可切除非小细胞肺癌新辅助免疫治疗研究进展［J］. 中国肺癌杂志, 2024, 27(2): 138-146.
［19］ Lei J, Zhao J B, Gong L, et al. Neoadjuvant camrelizumab plus Platinum-Based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage ⅢA or ⅢB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial［J］. JAMA Oncol, 2023, 9(10): 1348-1355.
［20］ Zhang X, Shao M, Yao J, et al. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer［J］. Future Oncol, 2024, 20(3): 121-129.
［21］ Shao M, Yao J, Wang Y, et al. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial［J］. Signal Transduct Target Ther, 2023, 8(1): 146.
［22］ Deng H, Zhao Y, Cai X, et al. PD-L1 expression and tumor mutation burden as pathological response biomarkers of neoadjuvant immunotherapy for early-stage non-small cell lung cancer: a systematic review and Meta-analysis［J］. Crit Rev Oncol Hematol, 2022, 170: 103582.

[1]	Wang Jusi, Song Weian, Di Shouyin, Liu Junqiang, Fan Boshi, Zhou Shaohua, Yue Caiying, Zhao Jiahua, Chen Siyu, Gong Taiqian. Efficacy of neoadjuvant chemotherapy combined with immunotherapy in the treatment of stage Ⅲ non-small cell lung cancer [J]. Journal of Capital Medical University, 2024, 45(4): 660-665.
[2]	Zhang Daqian, Zhang Xiaoxin, Ye Zichen, Xie Zhilan, Yang Jichun, Jiang Yu. Diagnostic value of artificial intelligence assisted diagnostic system for acute leukemia: a Meta-analysis [J]. Journal of Capital Medical University, 2024, 45(4): 693-700.
[3]	Huang Xiaohui, Wang Xinwei, Wu Jie. Predictive value of neutrophil to lymphocyte ratio and platelet count combined with D-dimer in the prognosis of children with severe pneumonia complicated with sepsis [J]. Journal of Capital Medical University, 2024, 45(4): 721-726.
[4]	Liu Chang, Xin Zhong, Yang Jinkui. Relationship between diet quality scores and all-cause mortality in diabetic patients of different genders [J]. Journal of Capital Medical University, 2024, 45(3): 406-412.
[5]	Zheng Ming , Wu Jianyou , Sima Yutong, Wang Xiangdong, Zhang Luo, . Comparison of clinical characteristics between odontogenic sinusitis patients with and without sinusitis symptoms [J]. Journal of Capital Medical University, 2024, 45(2): 239-245.
[6]	Li Xiaotong, Zhao Xiaobin, Lyu Ruijuan, Yuan Leilei, Chen Qian, Wang Qun, Ai Lin. 18F-FDG PET/CT imaging features of autoimmune encephalitis with anti-LGI1 antibody [J]. Journal of Capital Medical University, 2024, 45(1): 8-12.
[7]	Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer [J]. Journal of Capital Medical University, 2023, 44(5): 882-888.
[8]	He Sha, Yuan Mengwei, Gao Yan, Gou Dongyun, Li Yang, Qiu Huiqing. Association between ApoE gene polymorphism and cardiovascular and cerebrovascular diseases in Hebei Han nationality [J]. Journal of Capital Medical University, 2023, 44(5): 852-858.
[9]	Zhou Li, Zhu Chao, Wang Fucai, Cui Hehe, Liu Qingbo, Zhao Huiqiang, Chen Hui. Drug-coated balloons in primary percutaneous coronary intervention for acute myocardial infarction [J]. Journal of Capital Medical University, 2023, 44(4): 669-675.
[10]	Li Yuyang, Zhu Xiaorong, Liu Jing, Zheng Xiaomin, Yang Jinkui, Yang Fangyuan. Analysis of haptoglobin gene polymorphisms and serum haptoglobin levels in patients with diabetes kidney disease [J]. Journal of Capital Medical University, 2023, 44(3): 375-380.
[11]	Zhang Yudong, Wei Houyi, Wang Runjin, Jiang Mingxin, Yang Kun, Wang Mingshuai, Wasilijiang Wahafu, Song Liming, Jin Mulan, Xing Nianzeng, Niu Yinong. Prognostic significance of the controlling nutritional status (CONUT) score in patients with bladder cancer treated with radical cystectomy and ileal conduit [J]. Journal of Capital Medical University, 2023, 44(3): 449-456.
[12]	Zhao Huiqing, Zhang Yaqing. Investigation and analysis of migraine diagnosis and treatment in general practitioners [J]. Journal of Capital Medical University, 2023, 44(3): 482-486.
[13]	Liang Fa, Wu Youxuan, Wang Xinyan, Jian Minyu, Liu Haiyang, Han Ruquan. Effects of emergency conversion to general anesthesia on neurological outcomes of patients with acute ischemic stroke undergoing mechanical thrombectomy [J]. Journal of Capital Medical University, 2023, 44(2): 237-243.
[14]	Yin Hongyu , Wei Hua, Liu Jinchun. Role of retinoic acid and thyroid hormone in chondrogenic differentiation of bone marrow mesenchymal stem cells [J]. Journal of Capital Medical University, 2023, 44(2): 258-264.